MS CETSA深度功能蛋白质组学揭示了导致对gemcitabine耐药性的DNA修复程序
Ying Yu Liang1, Khalidah Khalid1, Hai Van Le1
1Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, 138673, Singapore.
淋巴瘤中的杰姆西塔耐药性涉及不同的细胞反应. 向ATR重新敏感化了耐药细胞,揭示了DNA损伤修复中的关键信号节点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 癌症药物耐药性涉及复杂的细胞生物化学.
- 在系统层面理解阻力机制是具有挑战性的.
- 吉姆西塔是扩散型大B细胞淋巴瘤的关键化疗剂.
研究的目的:
- 为了研究耐药和敏感淋巴瘤细胞中对gemcitabine的生化反应.
- 为了确定关键的分子途径,涉及到杰姆西塔耐药性.
- 探索潜在的治疗点,以克服耐 gemcitabine 的抵抗.
主要方法:
- 使用细胞热转移试验 (CETSA) 的深度功能蛋白质组学.
- 对耐吉他和敏感的扩散性大B细胞淋巴瘤细胞系生物化学变化的分析.
- 评估药物对细胞通路,细胞亡和DNA损伤反应的影响.
主要成果:
- 敏感细胞和耐药细胞都最初表现出gemcitabine对核糖核酸减少酶和DNA损伤的影响.
- 耐药细胞表现出明显的DNA损伤信号,细胞周期检查点激活和转化DNA合成.
- 在耐药细胞中诱导"辅助DNA损伤修复"蛋白质组合.
- 抑制ATR可以使耐凝素的细胞重新敏感.
结论:
- 耐吉他的特点是DNA损伤和修复途径中的特定生化适应.
- ATR信号传递是调解耐 gemcitabine 的关键节点.
- 向ATR提供了一种潜在的策略,以恢复耐药癌症中对gemcitabine的敏感性.
更多相关视频
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
相关概念视频
Treatment Resistant Cancers
Base Excision Repair
The first step of...
DNA Damage can Stall the Cell Cycle
Long-patch Base Excision Repair
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
